Acute effects of bromocriptine, cyproheptadine, and valproic acid on plasma adrenocorticotropin secretion in Nelson's syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 2, 1997, Pages 514-517

  Mercado Asis, Leilani B ^a,b   Yanovski, Jack A ^a,e   Tracer, Howard L ^a,c   Chik, Constance L ^a,d   Cutler Jr , Gordon B ^a,e  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b UNIVERSITY OF SANTO TOMAS   (Philippines)

^c University of Santo Tomas ^*  (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e USPHS Mailstop E32   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CORTICOTROPIN; CYPROHEPTADINE; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; FEMALE; HORMONAL REGULATION; HORMONE INHIBITION; HUMAN; NELSON SYNDROME; PRIORITY JOURNAL;

EID: 0031016399     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.2.514     Document Type: Article

References (39)

1. Nelson DH, Meakin JW, Dealy JB, Matson DD, Emerson K, Thorn GW. 1958 ACTH producing tumor of the pituitary gland. N Engl J Med. 259:161-164.
2. Aron DC, Findling JW, Fitzgerald PA, Forsham PH, Wilson CB, Tyrrell JB. 1982 Cushing's syndrome: problems in management. Endocr Rev. 3:229.
3. Sheline GE. 1979 Conventional radiation therapy in the treatment of pituitary tumors. In: Tindall GT, Collins WF, eds. Clinical management of pituitary disorders. New York: Raven Press; 297-300.
4. Cohen KL, Noth RH, Pechinski T. 1978 Incidence of pituitary tumors following adrenalectomy, a long-term follow-up study of patients treated for Cushing's disease. Arch Intern Med. 138:575.
5. Kasperlik-Zaluska AA, Nielubowics J, Wislawski J, et al. 1983 Nelson's syndrome: incidence and prognosis. Clin Endocrinol (Oxf). 19:693-698.
6. Moore TJ, Dluhy RG, Williams GH, Cain JP. 1976 Nelson's syndrome: frequency, prognosis and effect of prior irradiation. Ann Intern Med. 85;731-734.
7. Miller JW, Crapo L. 1993 The medical treatment of Cushing's syndrome. Endocr Rev. 14:443-458.
8. Dornhorst A, Jenkins JS, Lamberts SWJ, et al. 1983 The evaluation of sodium valproic acid in the treatment of Nelson's syndrome. J Clin Endocrinol Metab. 56:985-991.
9. Krieger DT, Luria M. 1976 Effectiveness of cyproheptadine in decreasing plasma ACTH concentrations in Nelson's syndrome. N Engl J Med. 43:1179.
10. Lamberts SWJ, Klijn JGM, de Quijada M, et al. 1980 The mechanism of the suppressive action of bromocriptine in adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome. J Clin Endocrinol Metab. 51:307.
11. Abraham RR, Campbell EA, Gillham B, et al. 1986 The effect of ovine corticotrophin releasing factor (oCRF), bromocriptine and TRH on the secretion of ACTH and a-MSH in Nelson's syndrome and Cushing's disease. Clin Endocrinol (Oxf). 25:75-85.
12. Ishibashi M, Yamaji T. 1981 Direct effects of thyrotropin-releasing hormone, cyproheptadine, and dopamine on adrenocorticotropin secretion from human corticotroph adenoma cells in vitro. J Clin Invest. 68:1018-1027.
13. Lamberts SWJ, Birkenhager JC. 1976 Effect of bromocriptine in pituitary-dependent Cushing's syndrome. J Endocrinol. 70:315-316.
14. Lamberts SWJ, Birkenhager JC. 1976 Bromocriptine in Nelson's syndrome and Cushing's disease. Lancet. 2:811.
15. Hale AC, Coates PJ, Doniach I, et al. 1988 A bromocriptine-responsive corticotroph adenoma secreting α-MSH in a patient with Cushing's disease. Clin Endocrinol (Oxf). 28:215-223.
16. Kennedy AL, Sheridan B, Montgomery DAD. 1978 ACTH and cortisol response to bromocriptine, and results of long-term therapy in Cushing's disease. Acta Endocrinol (Copneh). 89:461-468.
17. Mercado-Asis LB, Yasuda K, Murayama M, MuneT, Morita H, Miura K. 1992 Beneficial effects of high daily dose bromocriptine treatment in Cushing's disease. Endocrinol Jpn. 39:385-395.
18. Whitehead HM, Beacom R, Sheridan B, Atkinson AB. 1990 The effect of cyproheptadine and/or bromocriptine on plasma ACTH levels in patients cured of Cushing's disease by bilateral adrenalectomy. Clin Endocrinol (Oxf). 32:193-201.36.
19. Douglas WW. 1985 Histamine 5-hydroxytryptamine (serotonin) and their antagonists. In: Gilman AG, Goodman LS, Rall TW, Murad F, eds. The pharmacological basis of therapeutics, 7th ed. New York: Macmillan: 634-635.
20. Krieger DT, Amorosa L, Linick F. 1975 Cyproheptadine-induced remission of Cushing's disease. N Engl J Med. 293:893-896.
21. Plonk JW, Bivens CH, Feldman JM. 1974 Modification of adrenal function by the antiserotonin agent cyproheptadine. J Clin Endocrinol Metab. 38:836-840
22. Krieger DT, Condom EM. 1978 Cyproheptadine treatment of Nelson's syndrome: restoration of plasma ACTH circadian periodicity and reversal of response to TRF. J Clin Endocrinol Metab. 46:349-352.
23. Lankford HV, Tucker HSG, Blackard WG. 1981 A cyproheptadine-reversible defect in ACTH control persisting after removal of the pituitary tumor in Cushing's disease. N Engl J Med. 305:1244-1248.
24. Suda T, Tozawa F, Mouri T, et al. 1983 Effects of cyproheptadine, reserpine, and synthetic corticotropin-releasing factor on pituitary glands from patients with Cushing's disease. J Clin Endocrinol Metab. 56:1094-1099.
25. Cassar J, Mashitter K, Joplin GF, Rees LH, Gilkes, JJH. 1976 Cyproheptadine in Nelson's syndrome. Lancet. 2:426.
26. Nakashima H, Hirata Y, Uchihashi M, et al. 1985 Concomitant suppression of plasma ACTH and beta-endorphin-like immunoreactivity by cyproheptadine, naloxone and somatostatin in the ectopic ACTH syndrome. Horm Metab Res. 17:205-208.
27. Jones MT, Gillman B, Altaher ARH, et al. 1984 Clinical and experimental studies on the role of GABA in the regulation of ACTH secretion: a review Psychoneuroendocrinology. 9:107-123.
28. Acs Z, Stark E. 1978 Possible role of GABA synthesis in the mechanism of dexamethasone feedback action. J Endocrinol. 77:137-141.
29. Jones MT, Hillhouse EW, Burden JL. 1976 The effect of various putative neurotransmitters on the release of CRF from the rat hypothalamus in vitro. J Endocrinol. 69:1-10.
30. Godin Y, Heiner L, Madel P. 1969 Effect of di-n-propylacetate anti-convulsant compound on GABA metabolism. J Neurochem. 16:869-873.
31. Campbell EA, Altaher ARH, Scraggs PR, Gilman B, Jones MT. 1986 Effect of GABA transaminase inhibitors on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocr Perspect. 5:303-307.
32. Jones TJ, Gillman B, Beckford U, et al. 1981 Effect of treatment with sodium valproic acid and diazepam on plasma corticotropin in Nelson's syndrome. Lancet. 1:1179-1181.
33. Elias AN, Gwinup G, Valenta LJ. 1981 Effects of valproic acid, naloxone, and hydrocortisone in Nelson's syndrome and Cushing's disease. Clin Endocrinol (Oxf). 15:151-154.
34. Gomi M, Iida S, Itoh Y, et al. 1985 Unaltered stimulation of pituitary adrenocorticotropin secretion by corticotropin-releasing factor following sodium valproic acid administration in a patient with Nelson's syndrome. Clin Endocrinol (Oxf). 23:123-127.
35. Nussey SS, Price P, Jenkins JS, Altaher ARH, Gillham B, Jones MT. 1988 The combined use of sodium valproic acid and metyrapone in the treatment of Cushing's syndrome. Clin Endocrinol (Oxf). 28:373-380.
36. Nieman L, Chrousos G, Oldfield E, et al. 1986 The ovine corticotropin-releasing hormone, stimulation test, the dexamethasone suppression test in the differential diagnosis of Cushing syndrome. Ann Intern Med. 1105:862-867.
37. Krieger DT. 1976 Cyproheptadine for pituitary disorders. N Engl J Med. 295:394-395.
38. Cooper PR. 1991 Nonoperative management of prolactin-secreting pituitary adenomas. In: Cooper PR (ed) Contemporary diagnosis and management of pituitary adenomas. Park Ridge, IL: American Association of Neurological Surgeons; 83-100.
39. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. 1995 Clinical review 75: recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab. 80:3395-3402.